These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 39084081)

  • 61. Development of Thiazolidinedione-Based HDAC6 Inhibitors to Overcome Methamphetamine Addiction.
    Sharma C; Oh YJ; Park B; Lee S; Jeong CH; Lee S; Seo JH; Seo YH
    Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31835389
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.
    Rabal O; Sánchez-Arias JA; Cuadrado-Tejedor M; de Miguel I; Pérez-González M; García-Barroso C; Ugarte A; Estella-Hermoso de Mendoza A; Sáez E; Espelosin M; Ursua S; Haizhong T; Wei W; Musheng X; Garcia-Osta A; Oyarzabal J
    Eur J Med Chem; 2018 Apr; 150():506-524. PubMed ID: 29549837
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Targeted inhibition of histone deacetylase 6 in inflammatory diseases.
    Ran J; Zhou J
    Thorac Cancer; 2019 Mar; 10(3):405-412. PubMed ID: 30666796
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Computational Approach to Investigate the HDAC6 and HDAC10 Binding Propensity of Psidium guajava-derived Compounds as Potential Anticancer Agents.
    Adewole KE; Ishola AA
    Curr Drug Discov Technol; 2021; 18(3):423-436. PubMed ID: 32357815
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [HDAC6, a very specific deacetylase with a potential therapeutic role].
    Osseni A; Schaeffer L
    Med Sci (Paris); 2022 Dec; 38 Hors série n° 1():6-12. PubMed ID: 36649628
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Design, Synthesis, and Biological Evaluation of Novel Quinazolin-4(3H)-One-Based Histone Deacetylase 6 (HDAC6) Inhibitors for Anticancer Activity.
    Khetmalis YM; Fathima A; Schweipert M; Debarnot C; Bandaru NVMR; Murugesan S; Jamma T; Meyer-Almes FJ; Sekhar KVGC
    Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446224
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo.
    Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
    Eur J Med Chem; 2020 Mar; 190():112086. PubMed ID: 32058238
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
    Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L
    Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Design, Synthesis, and Pharmacological Evaluation of First-in-Class Multitarget N-Acylhydrazone Derivatives as Selective HDAC6/8 and PI3Kα Inhibitors.
    Rodrigues DA; Guerra FS; Sagrillo FS; de Sena M Pinheiro P; Alves MA; Thota S; Chaves LS; Sant'Anna CMR; Fernandes PD; Fraga CAM
    ChemMedChem; 2020 Mar; 15(6):539-551. PubMed ID: 32022441
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Multicomponent Synthesis, Binding Mode, and Structure-Activity Relationship of Selective Histone Deacetylase 6 (HDAC6) Inhibitors with Bifurcated Capping Groups.
    Reßing N; Sönnichsen M; Osko JD; Schöler A; Schliehe-Diecks J; Skerhut A; Borkhardt A; Hauer J; Kassack MU; Christianson DW; Bhatia S; Hansen FK
    J Med Chem; 2020 Sep; 63(18):10339-10351. PubMed ID: 32803970
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A potent hydroxamic acid-based, small-molecule inhibitor A452 preferentially inhibits HDAC6 activity and induces cytotoxicity toward cancer cells irrespective of p53 status.
    Ryu HW; Shin DH; Lee DH; Won HR; Kwon SH
    Carcinogenesis; 2018 Jan; 39(1):72-83. PubMed ID: 29106445
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine γ-lyase protein degradation.
    Chi Z; Byeon HE; Seo E; Nguyen QT; Lee W; Jeong Y; Choi J; Pandey D; Berkowitz DE; Kim JH; Lee SY
    Pharmacol Res; 2019 Aug; 146():104281. PubMed ID: 31125601
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Carboxylic acid derivatives display potential selectivity for human histone deacetylase 6: Structure-based virtual screening, molecular docking and dynamics simulation studies.
    Uba AI; Yelekçi K
    Comput Biol Chem; 2018 Aug; 75():131-142. PubMed ID: 29859380
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010-2020).
    Li Y; Sang S; Ren W; Pei Y; Bian Y; Chen Y; Sun H
    Eur J Med Chem; 2021 Dec; 226():113874. PubMed ID: 34619465
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Overview of the PRMT6 modulators in cancer treatment: Current progress and emerged opportunity.
    Peng J; Ni B; Li D; Cheng B; Yang R
    Eur J Med Chem; 2024 Dec; 279():116857. PubMed ID: 39276585
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Activation of MET signaling by HDAC6 offers a rationale for a novel ricolinostat and crizotinib combinatorial therapeutic strategy in diffuse large B-cell lymphoma.
    Liu Z; Cai Y; Yang Y; Li A; Bi R; Wang L; Shen X; Wang W; Jia Y; Yu B; Cao B; Cui W; Wei P; Zhou X
    J Pathol; 2018 Oct; 246(2):141-153. PubMed ID: 29876933
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Novel dual LSD1/HDAC6 inhibitors for the treatment of multiple myeloma.
    Naveen Sadhu M; Sivanandhan D; Gajendran C; Tantry S; Dewang P; Murugan K; Chickamunivenkatappa S; Zainuddin M; Nair S; Vaithilingam K; Rajagopal S
    Bioorg Med Chem Lett; 2021 Feb; 34():127763. PubMed ID: 33359604
    [TBL] [Abstract][Full Text] [Related]  

  • 78. HDAC6: A unique HDAC family member as a cancer target.
    Kaur S; Rajoria P; Chopra M
    Cell Oncol (Dordr); 2022 Oct; 45(5):779-829. PubMed ID: 36036883
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Discovery of Potent Selective HDAC6 Inhibitors with 5-Phenyl-1
    Li X; Wang C; Chai X; Liu X; Qiao K; Fu Y; Jin Y; Jia Q; Zhu F; Zhang Y
    J Chem Inf Model; 2024 Aug; 64(15):6147-6161. PubMed ID: 39042494
    [TBL] [Abstract][Full Text] [Related]  

  • 80. How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics.
    Zhang Y; Ying JB; Hong JJ; Li FC; Fu TT; Yang FY; Zheng GX; Yao XJ; Lou Y; Qiu Y; Xue WW; Zhu F
    ACS Chem Neurosci; 2019 May; 10(5):2467-2480. PubMed ID: 30784262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.